Ƶ

Mortality Reaches 20% for Hospitalized Patients With High-Risk Pulmonary Embolism

— Worst outcomes for patients with hemodynamic collapse

Ƶ MedicalToday
 A computer rendering of a thrombus in a blood vessel.

Mortality rates were high among patients with high-risk pulmonary embolism (PE), with the worst outcomes in those with hemodynamic collapse, according to a retrospective analysis of the Pulmonary Embolism Response Team (PERT) Consortium Registry.

In nearly 5,800 patients, in-hospital mortality occurred over five times more frequently among those with high-risk PE compared with those with intermediate-risk PE (20.6% vs 3.7%, P<0.001), reported Jay Giri, MD, MPH, of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and co-authors.

Similarly, the risk for major bleeding was also higher among high-risk PE patients versus intermediate-risk PE patients (10.5% vs 3.5%, P<0.001), they noted in the .

"In comparison with previous data reported in high-risk PE patients, several patterns emerge," Giri and team wrote. "First, our work confirms that high-risk PE patients are the predominant driver of observed short-term mortality in hospitalized PE patients."

"While prior observational studies of high-risk PE patients have demonstrated short-term mortality ranging from 30% to 50%, our study demonstrated a somewhat lower overall mortality rate of 20.6% in all high-risk patients," they continued. "This could be due to more complete capture of the entire high-risk spectrum in this registry, technological improvements in PE care, and/or improved care delivery methods in experienced PERT centers."

In an , Behnam N. Tehrani, MD, of Inova Schar Heart and Vascular in Falls Church, Virginia, and co-authors noted that PE remains one of the top causes of cardiovascular death in the U.S., but more research is needed to improve risk assessment models.

The findings from this study "should serve as an impetus for universally accepted definitions for high-risk PE and the pursuit of novel metrics to elucidate signals of efficacy, including durable changes in hemodynamics, metabolic measures of tissue perfusion, and echocardiographic and proteomic-based predictors of survival and myocardial recovery," they wrote.

In the study, multivariable regression analysis showed that there were a number of factors associated with in-hospital mortality:

  • Vasopressor use: OR 4.56, 95% CI 3.27-6.38, P<0.01
  • Extracorporeal membrane oxygenation (ECMO) use: OR 2.86, 95% CI 1.12-7.30, P=0.03
  • Identified clot-in-transit: OR 2.26, 95% CI 1.13-4.52, P=0.02
  • Malignancy: OR 1.70, 95% CI 1.13-2.56, P=0.01

Giri and colleagues also found that patients presenting with catastrophic PE had greater in-hospital mortality than their non-catastrophic counterparts (42.1% vs 17.2%, P<0.001), and ECMO (13.3% vs 4.8%, P<0.001) and systemic thrombolysis (25% vs 11.3%, P<0.001) were used more commonly in catastrophic PE.

Data for this study were taken from the PERT Consortium Registry, which includes patients from all 35 active U.S. registry sites admitted from Oct. 16, 2015 to April 8, 2022. Of the 5,790 patients in the study, 1,442 presented with high-risk PE and 2,976 presented with intermediate-risk PE.

Approximately half of the patients were men, and the average patient age was 63 years. Over half of the patients in both the high- and intermediate-risk cohorts were white.

High-risk PE patients were defined as those who, on initial hospital presentation, experienced hemodynamic collapse, hypotension, sustained systolic blood pressures <90 mm Hg, or the need for vasopressor support. Catastrophic patients additionally needed to have hemodynamic collapse that ultimately necessitated use of high-dose vasopressors due to concerns for impending cardiac arrest or those experiencing cardiac arrest with or without cardiopulmonary resuscitative efforts.

Intermediate-risk patients were defined as having systolic blood pressures >90 mm Hg, as well as evidence of right ventricular strain and/or biomarker abnormalities.

Giri and team noted that use of the PERT Consortium Registry may have excluded patients admitted to the hospital for PE who did not have previous consultations associated with the registry. Other potential limitations to the study included the fact that patients in the registry may have spent less time in the intensive care unit and may have had a shorter length of stay due to utilization of advanced therapies.

  • author['full_name']

    Elizabeth Short is a staff writer for Ƶ. She often covers pulmonology and allergy & immunology.

Disclosures

This study was funded through a grant from the PERT Consortium, a 501(c)3 not-for-profit organization.

Giri reported relationships with Boston Scientific, Abbott Vascular, Recor Medical, Inari Medical, Edwards, Abiomed, and Endovascular Engineering. Co-authors also reported multiple relationships with industry.

Tehrani reported relationships with Boston Scientific and Abbott Medical. A co-author reported relationships with Boston Scientific, Abbott, Medtronic, Edwards, Idorsia, and Recor.

Primary Source

Journal of the American College of Cardiology

Kobayashi T, et al "Contemporary management and outcomes of patients with high-risk pulmonary embolism" J Am Coll Cardiol 2024; DOI: 10.1016/j.jacc.2023.10.026.

Secondary Source

Journal of the American College of Cardiology

Tehrani BN, et al "High-risk acute pulmonary embolism: where do we go from here?" J Am Coll Cardiol 2024; DOI: 10.1016/j.jacc.2023.11.001.